Jackson County Medical Control Authority MICU Protocols NESIRITIDE (NATRECOR)

Date: December 2017 Page 1 of 1

Nesiritide (Natrecor)

Indications:

Acutely decompensated congestive heart failure patients who have

dyspnea at rest or with minimal activity.

Contra-indications:

Hypersensitivity to any of its components and it should be avoided in patients suspected of having, or known to have, low cardiac filling pressure. Nesiritide should not be used as primary therapy for patients with known cardiogenic shock or patients

with SBP less than 90mmHg.

Adverse Effects:

Prolonged hypotension (mean duration of greater than 2 hours in

length).

Administration:

Initial bolus of 2 mcg/kg (over 60 seconds) followed by an infusion of 0.01mcg/kg/min. *Nesiritide should not be titrated. If hypotension is observed discontinue infusion* (mix 1.5mg of reconstituted Nesiritide in 250ml D5W or 0.9%NS. this will give

you a concentration of 6 mcg/ml).

Patient Weight

i duent Weight						
	60kg	70kg	80kg	90kg	100kg	110kg
Bolus (ml/60sec)	20	23.3	26.7	30	33.3	36.7
	60kg	70kg	80kg	90kg	100kg	110kg
inf. rate (ml/hr)	6	7	8	9	10	11

MICU Directives:

- 1. Follow generalized protocol for MICU transports.
- 2. Maintain appropriate delivery rate by IV infusion pump.
- 3. Monitor vital signs every 5-10 minutes.
- Discontinue and notify appropriate medical direction facility if patient develops severe hypotension or hypersensitivity occurs.
- 5. If an invasive arterial line monitoring device is present and compatible with MICU equipment, continue monitoring during transport.